Fig. 3From: Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in JapanOngoing adalimumab (ADA) treatment rate. A total of 10 patients discontinued treatment due to primary nonresponse (n = 1), secondary nonresponse (n = 2), or an adverse event (n = 7). The ADA ongoing treatment rate at 52 weeks was 83.9 %Back to article page